Clinical Research Associate 3 - Clinical Research Associate
About the job
- A Bachelor's degree is required.
- At least 5 years of experience directly supporting clinical research involving an implantable medical device, or similar experience in a medical or scientific area, is required.
- At least 2 years of experience monitoring clinical trial sites is required.
- Deep knowledge of Good Clinical Practice and regulatory compliance guidelines for clinical trials is required.
- Effective comprehension of medical terminology is required.
- The role requires high attention to detail and accuracy.
- The candidate must be able to manage multiple tasks and work independently.
- The candidate must manage tasks and duties efficiently and expediently.
- The candidate must maintain high standards of ethics and integrity.
- The candidate must work effectively across functions while maintaining high performance standards.
- The candidate must be comfortable working in a small company and able to thrive in a high-growth environment.
- Sophisticated written and oral communication skills are required.
- Effective problem-solving skills are required.
- The candidate must be adaptable, resourceful, and comfortable navigating change.
- An entrepreneurial approach is required.
- The candidate must be able to travel within the United States by car and air, with travel up to 40% stated in the required qualifications.
- The candidate must possess a valid government-issued ID for domestic air travel.
- The candidate must have a valid driver's license and reliable transportation.
- The candidate must have a professional home-office environment that supports confidential and private work when working from home.
- The candidate must be legally authorized to work in the United States without current or future employment visa sponsorship.
- Normal office conditions and a reliable high-speed internet connection are required when working in a home office.
- The candidate must be able to sit, stand, or walk for 8 hours per day.
- The candidate may be required to be fully vaccinated against COVID-19 and other diseases.
- Develop and maintain successful working relationships with study sites and serve as the primary point of contact.
- Assist in preparing study materials and training investigators and site staff.
- Support Clinical Centers with site Institutional Review Board or ethics committee submissions.
- Collect and track required regulatory documents from Clinical Centers as assigned.
- Coordinate and conduct monitoring at participating centers according to the monitoring plan, ensuring compliance with the protocol and applicable regulations and timely receipt of accurate data and required study documents.
- Prepare and submit high-quality monitoring reports according to study-specific requirements.
- Evaluate site performance using enrollment trends, data-quality metrics, protocol deviations, product accountability, and patient-safety parameters.
- Support sites with adverse event and serious adverse event identification, documentation, and reporting.
- Verify timely submission of required safety documentation, device complaint forms, and follow-up queries.
- Proactively identify site-level risks and support the execution of risk-mitigation plans.
- Source and verify clinical data and information, and oversee data correction against source records.
- Maintain Clinical Study files.
- Manage device accountability at sites when applicable.
- Process payments to sites, vendors, and consultants.
- Review clinical data and information and oversee data correction.
- Review center activation documentation.
- Coordinate with Clinical Project Managers, Data Management, Safety, Regulatory, Quality, and Training to support end-to-end study execution.
- Provide operational input on protocol development, case report forms, risk assessments, monitoring plans, investigational brochures, and essential document requirements.
- Collaborate on Trial Master File quality checks to ensure site-level documentation is complete, audit-ready, and compliant.
- Contribute to process-improvement initiatives, quality management system updates, and clinical operations optimization.
- Assist management with metrics reporting, monitoring dashboards, and early risk detection through data analytics.
- Participate in vendor oversight for central laboratories, imaging, and core laboratories to ensure site compliance when applicable.
- Assist with training new Clinical Research Associates.
- Assist with the successful conduct of assigned studies, interfacing with representatives from Regulatory Affairs and Quality Assurance, Research and Development, U.S. Market Development, Commercial Development, and Clinical Research Organizations.
- Provide internal team members with mentoring on site monitoring.
- Complete special projects and other job-related duties as assigned.
- An advanced degree in a related field is preferred.
About the company
CVRx develops BAROSTIM NEO, a neuromodulation therapy for heart failure. The device delivers electrical stimuli to baroreceptors in the cardiovascular system to modulate nerve activity and support blood pressure regulation, aiming to improve heart function in patients who struggle with fatigue, shortness of breath, and fluid retention. The system works through an implanted or wearable neuromodulation device that interacts with the body's nerve signals to influence cardiovascular control. CVRx differentiates itself by offering a focused solution for heart failure that combines the device with provider-focused support programs to facilitate patient access and reimbursement, working with hospitals and clinics to implement therapy. The company's goal is to improve patient outcomes for heart failure and expand the adoption of BAROSTIM THERAPY by helping healthcare providers treat more patients effectively.
Company Size
201-500
Company Stage
IPO
Headquarters
Minneapolis, Minnesota
Founded
2001
Get referred to CVRx
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 16% to $15.7 million, despite tougher commercial execution.
- Traditional Medicare paid roughly 96% of Barostim claims, improving reimbursement reliability.
- HFSA 2026 features eight Barostim presentations, supporting physician awareness and evidence expansion.
What critics are saying
- DoJ issued a civil investigative demand in May 2026 over sales and marketing practices.
- CVRx cut 2026 revenue guidance to $58-$60 million after sales-force turnover and slow ramps.
- A major Medicare Advantage payer crushed 30-day approvals below 30%, threatening Barostim adoption.
What makes CVRx unique
- Barostim remains the only FDA-approved neuromodulation therapy for heart failure, August 2026.
- CVRx owns a clinically validated baroreflex platform with growing HFSA 2026 evidence.
- Pointillist Family Office called Barostim a deep-moat asset, underscoring strategic scarcity.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Stock Options
Company Equity
Paid Holidays
Parental Leave
Flexible Work Hours
Remote Work Options
Training Programs
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↓ -1%CVRx announces late-breaking data and new clinical evidence on Barostim at the HFSA Annual Scientific Meeting 2026. GlobeNewswire | CVRx, Inc. Today at 1:30pm PDT MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix. Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an expanded population, will also be included in the clinical trial ePoster hub. New REBALANCE Registry and Real-World HFmrEF Evidence In a late-breaking session, Dr. Dmitry Yaranov will present new analyses from the REBALANCE Registry, the largest real-world study of Barostim-treated patients to date, evaluating the safety and benefits of Barostim in commercial use. In a separate rapid-fire session, Dr. Javed Butler will present Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden. In addition to the REBALANCE and HFmrEF presentations, Barostim will be featured in numerous scientific sessions and activities throughout the HFSA Annual Scientific Meeting 2026. Barostim on the HFSA Annual Scientific Meeting 2026 Agenda Friday, Oct. 9: * Devices in Heart Failure Meeting, Discussion Forum - Making a Choice CCM or Barostim (Dr. Elizabeth Volz and Dr. Omar Cantu Martinez) * Devices in Heart Failure Meeting, Trial Tinder: Choose my Trial! - BENEFIT-HF (Dr. Farooq Sheikh) * ePoster, Barostim Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) (Dr. William Abraham) Saturday, Oct. 10: * Poster, Interaction Testing Between Barostim Neo Device and Assure Wearable Cardiac Defibrillator (Dr. Rhea Verma) Sunday, Oct. 11: * Sunday Plenary Session, The REBALANCE Registry: Real World Outcomes Following Baroreflex Activation Therapy (Dr. Dmitry Yaranov) * Rapid Fire Session 2, Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden (Dr. Javed Butler) * Poster, Optimizing Management of Heart Failure with Reduced Ejection Fraction Using Baroreflex Activation Therapy: A Path to Diuretic Independence (Dr. Shreya Srivastava) Monday, Oct. 12: * Game of Thrones House of Devices: Restoring the Realm's Failing Hearts, House Lannister: Barostim Takes Up Arms (Dr. Sarah Chuzi) CVRx Sponsored Programs CVRx will host two symposia sharing insights on Barostim's role in the heart failure care continuum and its integration into clinical practice. On Friday, Oct. 9 from 7:00-8:30 a.m., Device-Based Neurohormonal Intervention: The Role of Barostim in Heart Failure Care will explore the clinical evidence supporting Barostim, patient selection, integration into guideline-directed care and practical considerations for implementation. On Sunday, Oct. 11 from 1:00-2:00 p.m., Successful Barostim Program Development: A Critical Component of the Heart Failure Care Continuum will address multidisciplinary collaboration, patient identification, referral pathways, workflow integration and best practices for developing and sustaining a successful Barostim program. "We are excited by the scientific interest in Barostim at this year's HFSA conference, with four separate data sets, five podium discussions and two symposia focused on practical elements for incorporating Barostim into clinical practice," said Kevin Hykes, President and Chief Executive Officer of CVRx. "The data being presented provide important new scientific insights about Barostim across patient populations, clinical outcomes and real-world practice, contributing to a broader understanding of its role in the heart failure continuum." About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim(TM) is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike Vallie ICR Healthcare 443-213-0501 [email protected] Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
CVRx, Inc. (NASDAQ:CVRX) stock has consensus target price of $4.30 according to analysts. September 26, 2026 Key points. * Analyst consensus is "Hold" among six firms, with one sell, three hold, and two buy ratings; the average 12-month price target is $4.30. * Several analysts recently downgraded CVRx or reduced targets, with price objectives ranging from $3.50 to $5.00. Shares opened at $2.70, near the $2.20 one-year low and well below the $11.30 high. * CVRx reported a quarterly loss of $0.53 per share, slightly missing estimates, while revenue of $15.71 million exceeded expectations. COO Brent Binkowski bought 26,223 shares, and insiders and institutions own 16.60% and 75.27% of the stock, respectively. * MarketBeat previews top five stocks to own in October. CVRx, Inc. (NASDAQ:CVRX - Get Free Report) has earned an average rating of "Hold" from the six ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $4.30. Several research firms have commented on CVRX. Wall Street Zen downgraded shares of CVRx from a "hold" rating to a "sell" rating in a report on Sunday, September 20th. Lake Street Capital lowered CVRx from a "buy" rating to a "hold" rating and cut their price target for the stock from $14.00 to $3.50 in a report on Friday, August 7th. Craig Hallum downgraded CVRx from a "buy" rating to a "hold" rating and set a $4.00 target price for the company. in a research note on Friday, August 7th. Canaccord Genuity Group set a $5.00 price objective on shares of CVRx in a research report on Tuesday. Finally, Piper Sandler cut shares of CVRx from an "overweight" rating to a "neutral" rating and set a $4.00 price objective for the company. in a research note on Friday, August 7th. Insider buying and selling. In other news, COO Brent Binkowski purchased 26,223 shares of CVRx stock in a transaction dated Thursday, August 13th. The stock was purchased at an average cost of $2.91 per share, for a total transaction of $76,308.93. Following the transaction, the chief operating officer directly owned 56,514 shares of the company's stock, valued at approximately $164,455.74. This trade represents a 86.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 16.60% of the stock is currently owned by insiders. Institutional investors weigh in on CVRx. Several large investors have recently added to or reduced their stakes in CVRX. Bank of America Corp DE purchased a new stake in shares of CVRx in the 2nd quarter valued at about $102,000. BlackRock Inc. bought a new position in shares of CVRx in the second quarter worth approximately $6,402,000. Deutsche Bank AG bought a new position in shares of CVRx in the second quarter worth approximately $62,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in CVRx in the second quarter valued at approximately $107,000. Finally, Bank of New York Mellon Corp bought a new position in shares of CVRx in the 2nd quarter worth $199,000. Institutional investors own 75.27% of the company's stock. CVRx price performance. Shares of NASDAQ CVRX opened at $2.70 on Friday. The company has a current ratio of 8.04, a quick ratio of 6.87 and a debt-to-equity ratio of 2.94. The stock has a fifty day simple moving average of $3.54 and a two-hundred day simple moving average of $5.55. CVRx has a 1-year low of $2.20 and a 1-year high of $11.30. The firm has a market cap of $71.93 million, a price-to-earnings ratio of -1.36 and a beta of 0.76. CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.01). The firm had revenue of $15.71 million for the quarter, compared to analysts' expectations of $15.55 million. CVRx had a negative net margin of 84.93% and a negative return on equity of 152.35%. Analysts anticipate that CVRx will post -2 earnings per share for the current year. CVRx company profile. CVRx, Inc is a medical device company that develops and commercializes neuromodulation therapies for patients with cardiovascular diseases. The company's technology is designed to use the body's nervous system to help regulate cardiovascular function and address conditions that may not be adequately managed with conventional drug therapy. CVRx's primary product is Barostim, an implantable system that electrically stimulates the baroreceptors located near the carotid arteries. The therapy is intended to activate the body's natural cardiovascular regulation mechanisms and is used primarily in eligible patients with heart failure, including certain patients with reduced ejection fraction. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider CVRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVRx wasn't on the list. While CVRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat
CVRx appoints John Landry as Chief Financial Officer. Landry brings two decades of medtech and public company finance experience. September 21, 2026 16:07 ET | Source: CVRx, Inc. MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q for the quarter ending September 30, 2026. Mr. Oasheim will remain with the Company for a transition period consistent with his previously disclosed transition agreement. "John is exactly the kind of finance leader we need for this next chapter," said Kevin Hykes, President and CEO of CVRx. "Over the past two decades, he has played a key role in building and financing high growth medical device companies introducing novel therapies like Barostim. He is a hands-on operational leader who has significant commercial and capital markets experience, and who is well known within the investment community. John's experience driving growth while managing expenses is particularly relevant as we scale Barostim and reach more heart failure patients. "I want to thank Jared for the significant impact he has had at the company since 2015. He led us through our IPO and helped build the financial foundation we stand on today," Hykes added. "We're grateful for his contributions and wish him success in his next chapter." Mr. Landry brings more than two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), where he raised several rounds of capital and drove operational efficiencies to fund the company's U.S. commercial expansion. Before that, he spent 12 years at Vapotherm, Inc. (formerly NYSE: VAPO), most recently as Senior Vice President and CFO, where he led the company's IPO and built its finance, investor relations and public company reporting functions from the ground up. Earlier in his career, Mr. Landry held finance leadership roles at Salient Surgical Technologies (acquired by Medtronic in 2011), Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand. He holds a B.S. in Accountancy from Bentley College, is a CPA (inactive) and serves on the board of Liberate Medical, Inc. "Barostim is changing how physicians treat heart failure and the positive impact it is having on patients' lives is what drew me to this role," said John Landry. "I've spent most of my career in the medical device industry helping to build the infrastructure and operating discipline needed as companies scale their commercial efforts. I'm excited to join the CVRx team and see a real opportunity to bring that same operating discipline to support the business as we execute our commercial growth strategy." About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim(TM) is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner ICR Healthcare 443-213-0501 [email protected] Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 [email protected]
CVRx reported second-quarter 2026 revenue of $15.7 million, up 16% year-over-year, with an 87% gross margin. However, the medical device company lowered its full-year revenue guidance due to anticipated weakness in the second half of the year. CEO Kevin Hykes attributed the revised outlook to challenges with sales force integration. The company maintained 56 US sales territories, but approximately 60% of quota-carrying territory managers joined within the past 18 months. This rapid hiring pace has strained onboarding and training processes. The company cited high turnover rates, slower productivity ramp-up for new hires, and concentration of new employees in specific regions as primary factors affecting performance. Despite these challenges, regions with stable leadership and experienced teams are achieving strong double-digit growth, suggesting the company's strategy remains sound where properly executed.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, encourages CVRx Inc. (CVRX) Investors with substantial losses to Contact firm: investigating potential securities fraud following 59% stock drop. SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) - Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer. CVRx Inc. (NASDAQ: CVRX) Investors: Investors who suffered substantial losses are encouraged to submit your losses now to evaluate their legal rights and recovery options. * Visit: www.hbsslaw.com/cases/cvrx * Contact Partner Reed Kathrein: 844-916-0895 | [email protected] INVESTIGATION OVERVIEW: CVRx Inc. (NASDAQ: CVRX) "We are investigating whether there is a direct connection between the Department of Justice CID and the immediate termination of the Chief Revenue Officer,..." CVRx's sole commercial product is Barostim, an FDA-approved implantable neuromodulation device designed to improve symptoms for patients suffering from heart failure. Historically, CVRx assured investors that its growth strategy was anchored by a complete sales force transformation and high approval rates from Medicare Advantage payers. CVRx repeatedly highlighted a "$10.5 billion market opportunity" with less than 1% penetration, reassuring the market earlier this year that its sales force transformation was "largely complete." However, after market close on August 6, 2026, CVRx disclosed a series of severe operational and legal headwinds: * DOJ Civil Investigative Demand (CID): On May 14, 2026, CVRx received a CID from the U.S. Department of Justice investigating whether the company caused the submission of false claims to government health programs by improperly marketing Barostim, paying kickbacks to healthcare providers, or submitting false information. * Sales Force Deterioration & Guidance Cut: CVRx significantly cut its 2026 revenue expectations and revealed serious problems with its salesforce - sequentially flat growth in sales territories, turnover, and strained onboarding and training. * Medicare Advantage Approval Collapse: CVRx revealed that its primary Medicare Advantage payer - which historically approved 80% of prior authorizations within 30 days - increased initial denials and reduced 30-day approvals to just 25%. In response to these revelations, CVRx's stock price cratered 59% on August 7, 2026. Three days later, on August 10, 2026, CVRx abruptly terminated its Chief Revenue Officer (CRO), Robert John. FOCUS OF THE HAGENS BERMAN INVESTIGATION "We are investigating whether there is a direct connection between the Department of Justice CID and the immediate termination of the Chief Revenue Officer, as well as whether CVRx may have misled investors regarding the true state of its commercial sales force and Medicare Advantage reimbursement rates," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. WHAT CVRx (CVRX) INVESTORS & WHISTLEBLOWERS CAN DO * Investors: If you invested in CVRx, Inc. (NASDAQ: CVRX) and suffered significant financial losses, you can submit your losses now. * Whistleblowers: Persons with non-public information regarding CVRx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.